BioVie Inc.
| NASDAQ: BIVI | Healthcare / Biotechnology / USA |
| 3.43 | +0.0124 | +0.36% | Vol 171.89K | 1Y Perf 40.74% |
| Oct 3rd, 2023 15:51 DELAYED |
| BID | 3.41 | ASK | 3.44 | ||
| Open | 3.32 | Previous Close | 3.42 | ||
| Pre-Market | 3.47 | After-Market | - | ||
| 0.05 1.46% | - - |
| Target Price | 9.75 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 184.26 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.06 | Earnings Rating | — | |
| Market Cap | 126.33M | Earnings Date | 3rd Nov 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.46 | |
| Beta | 1.71 |
Today's Price Range 3.213.50 | 52W Range 2.3414.38 | 5 Year PE Ratio Range -2.20-0.9000 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.12% | ||
| 1 Month | 10.68% | ||
| 3 Months | -18.96% | ||
| 6 Months | -53.15% | ||
| 1 Year | 40.74% | ||
| 3 Years | -63.50% | ||
| 5 Years | -60.91% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 1.50K | |||
ROE last 12 Months | -236.37 | |||
ROA (5Y Avg) | -224.28 | |||
ROA last 12 Months | -138.10 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -107.24 | |||
Return on invested Capital Q | -54.12 | |||
Return on invested Capital Y | -38.11 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.00 | ||||
| 32.80 | ||||
| - | ||||
| - | ||||
| -9.30 | ||||
| -1.01 | ||||
| 40.68 | ||||
| 0.18 | ||||
| 187.13M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.20 | ||||
| 5.30 | ||||
| 0.68 | ||||
| 2.15 | ||||
| -8.60 | ||||
| Leverage Ratio | 4.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2023 | -0.37 | -0.23 | 37.84 |
| Q03 2023 | -0.31 | -0.43 | -38.71 |
| Q01 2023 | - | -0.38 | - |
| Q03 2022 | -0.52 | -0.28 | 46.15 |
| Q02 2022 | -0.41 | -0.22 | 46.34 |
| Q02 2021 | -0.12 | -0.22 | -83.33 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 3rd Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 171.89K |
| Shares Outstanding | 36.80K |
| Shares Float | 13.17M |
| Trades Count | 1.53K |
| Dollar Volume | 581.06K |
| Avg. Volume | 255.98K |
| Avg. Weekly Volume | 294.48K |
| Avg. Monthly Volume | 262.98K |
| Avg. Quarterly Volume | 210.48K |
BioVie Inc. (NASDAQ: BIVI) stock closed at 3.42 per share at the end of the most recent trading day (a 0.29% change compared to the prior day closing price) with a volume of 260.08K shares and market capitalization of 126.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. BioVie Inc. CEO is Terren S. Peizer.
The one-year performance of BioVie Inc. stock is 40.74%, while year-to-date (YTD) performance is -55.98%. BIVI stock has a five-year performance of -60.91%. Its 52-week range is between 2.3417 and 14.38, which gives BIVI stock a 52-week price range ratio of 9.06%
BioVie Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 32.80, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -138.10%, a ROC of -107.24% and a ROE of -236.37%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BioVie Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BioVie Inc.’s next earnings report date is 03rd Nov 2023.
The consensus rating of Wall Street analysts for BioVie Inc. is Strong Buy (1), with a target price of $9.75, which is +184.26% compared to the current price. The earnings rating for BioVie Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioVie Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioVie Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.16, ATR14 : 0.32, CCI20 : 69.04, Chaikin Money Flow : -0.18, MACD : -0.10, Money Flow Index : 39.91, ROC : -1.16, RSI : 51.68, STOCH (14,3) : 71.84, STOCH RSI : 0.90, UO : 51.98, Williams %R : -28.16), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioVie Inc. in the last 12-months were: Cuong Do (Sold 0 shares of value $0 ), Richard J. Berman (Sold 10 984 shares of value $93 581 )
BioVie Inc.
BioVie Inc is active in the healthcare domain in the United States. The company is a development stage enterprise engaged in the discovery, development, and commercialization of a therapy targeting ascites due to liver cirrhosis. Its therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis. BioVie is developing BIV201 for alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and reducing the signals to the kidneys to retain excess salt and water.
CEO: Terren S. Peizer
Telephone: +1 312 283-5793
Address: 2120 Colorado Avenue, Santa Monica 90404, CA, US
Number of employees: 4
